Your dog has been vomiting repeatedly. Their weight keeps dropping despite eating. The stomach discomfort keeps recurring, and nothing you have tried has resolved it completely.
You have already ruled out the obvious causes. Dietary sensitivity. Parasites. A passing stomach upset. But the symptoms keep returning, and the picture keeps getting slightly harder to explain away.
Some gastrointestinal conditions in dogs are not about the structure of the gut itself. They are about what certain rare cells inside that gut are doing, specifically, cells that should be regulating hormone secretion quietly in the background, but have instead begun multiplying abnormally and producing hormones without any regulatory control.
These tumors are called apudomas. They are rare. They are complex. And because they affect the body through hormonal disruption rather than purely through mechanical obstruction, they can produce a symptom picture that is genuinely difficult to connect to a specific cause without the right diagnostic investigation.
This guide explains apudomas in dogs completely, what they are, where they come from, what they do to the body, and how veterinarians approach their diagnosis and management.
What Is an Apudoma in Dogs?
The term apudoma comes from the acronym APUD, which stands for Amine Precursor Uptake and Decarboxylation. APUD cells are a specialised population of neuroendocrine cells scattered throughout the body, with a significant concentration in the gastrointestinal tract.
These cells are remarkable in what they do. They sit at the intersection of the nervous system and the endocrine system, capable of both receiving neural signals and producing peptide hormones that regulate digestion, metabolism, acid secretion, gut motility, and nutrient absorption. In a healthy dog, they function as part of a precisely calibrated regulatory system that keeps the digestive process running properly.
An apudoma forms when APUD cells in the gastrointestinal tract begin proliferating abnormally. The resulting tumor is not simply a mass occupying space in the intestinal wall. It is a functionally active mass, one that continues to produce the hormones and peptides that normal APUD cells produce, but now without the regulatory mechanisms that would control how much is released and when.
The consequences depend on which hormones the tumor is secreting, how much it is producing, and which downstream systems are being disrupted. This is what makes apudomas clinically unusual. They do not just cause problems by being physically present. They cause problems by being hormonally active.
Apudomas in dogs are rare. They are among the less frequently encountered gastrointestinal tumors in veterinary medicine. But their rarity makes them easier to miss, and missing them has real consequences because the hormonal disruption they cause progresses over time and produces secondary damage, including ulceration and intestinal injury, that compounds the clinical picture.
Where Apudomas Occur in Dogs
Intestinal Neuroendocrine Tumors
Within the gastrointestinal tract, apudomas can develop in the walls of the stomach, the small intestine, and the large intestine. The neuroendocrine cells from which they arise are distributed throughout these structures, which means no single location is uniquely susceptible.
Apudomas developing within the intestinal wall typically begin as small, discrete nodules embedded in the deeper layers of the gut. As they grow, they may expand inward toward the intestinal lumen, outward toward the abdominal cavity, or infiltrate the wall layers themselves.
Their effects on the intestinal structure depend on their growth pattern and their hormonal output. A purely structural apudoma acting like a mechanical mass might narrow the intestinal lumen or compress adjacent tissue. But most apudomas in the gastrointestinal tract are hormonally active, and it is this activity that drives the most distinctive aspects of their clinical presentation.
Hormone-Producing Apudomas
The defining characteristic of most clinically significant apudomas is their ability to secrete biologically active hormones or peptides into the bloodstream and directly into the surrounding tissue.
Different APUD cell subtypes produce different regulatory molecules. Some produce gastrin, the hormone that stimulates stomach acid secretion. Gastrin-secreting apudomas, known as gastrinomas, drive excessive acid production that can cause severe, treatment-resistant gastric and intestinal ulceration. The resulting ulcers may bleed chronically, produce acute haemorrhage, or perforate the intestinal wall in severe cases.
Other apudomas may produce substances that affect gut motility, alter nutrient absorption, disrupt blood glucose regulation, or produce more generalised systemic hormonal effects. The specific hormonal product of the tumor shapes the clinical syndrome the dog develops, which is part of why apudomas can look so different from dog to dog despite arising from the same cell population.
This hormonal activity is also what can make apudomas diagnostically challenging. A dog presenting with severe gastric ulceration, chronic vomiting, and weight loss may initially be investigated and managed as a straightforward ulcer case before the underlying hormonal driver is identified. For context on how gastric and intestinal ulceration presents and is managed in dogs, VOSD’s article on stomach and intestinal ulcers in dogs provides relevant background.
Symptoms of Intestinal Apudomas in Dogs
The symptoms of apudomas are driven by a combination of the tumor’s physical presence in the gut and its hormonal output. Both factors vary by tumor location and type, which produces a clinical picture that can differ considerably between affected dogs.
What is consistent is that the symptoms tend to be persistent, progressive, and often resistant to standard symptomatic treatment. A dog whose vomiting or weight loss keeps returning despite appropriate management for common gastrointestinal conditions is a dog that deserves further investigation.
Gastrointestinal Symptoms
The digestive symptoms of apudomas reflect the tumor’s direct and indirect effects on the gastrointestinal tract:
- Chronic or recurrent vomiting that does not respond as expected to standard anti-nausea or dietary management
- Persistent diarrhoea, which may be watery or voluminous in dogs with apudomas producing hormones that affect intestinal secretion and motility
- Signs of acid reflux, including excessive swallowing, lip licking, grass eating, and regurgitation, particularly in dogs with gastrin-secreting tumors driving excessive stomach acid production
- Blood in the vomit or stool, which may indicate ulceration caused by elevated gastric acid or direct tumor surface bleeding
- Abdominal pain displayed as reluctance to be touched on the belly, a hunched or guarded posture, restlessness after eating, or audible discomfort when the abdomen is palpated
- Abdominal sounds including increased borborygmi or rumbling reflecting abnormal gut motility
- Reduced appetite or complete anorexia in dogs where the hormonal effects of the tumor have significantly disrupted normal digestive signalling
The persistence and treatment resistance of these symptoms are clinically significant. A dog that vomits intermittently and recovers is different from a dog whose vomiting returns every few days regardless of what dietary or medical management is applied. The latter pattern warrants imaging and further investigation rather than continued symptomatic treatment.
Whole-Body Symptoms
Beyond the gut, apudomas produce systemic effects that reflect both the nutritional consequences of impaired digestion and the broader metabolic disruption caused by abnormal hormone secretion:
- Progressive weight loss over weeks to months, often disproportionate to the apparent reduction in food intake
- Generalised lethargy and reduced engagement with normal activities
- Weakness and reduced exercise tolerance as nutritional depletion and anaemia develop
- Pale gums indicating anaemia from chronic intestinal blood loss caused by tumor-associated ulceration
- Episodes of fever in some cases, reflecting secondary infection or inflammatory responses associated with the tumor
- Dehydration from chronic fluid loss through vomiting and diarrhoea
- In some dogs with specific hormonal tumor types, signs related to the particular hormone being overproduced, such as hypoglycaemia-like episodes in dogs with insulin-like peptide secretion or signs of other metabolic disruption
The combination of persistent gastrointestinal symptoms with progressive weight loss and systemic deterioration in an older dog is a pattern that should always prompt thorough investigation rather than continued empirical management.
Related Videos
Causes of Apudomas in Dogs
The cellular origin of apudomas is understood. What is less clear is precisely what triggers the abnormal proliferation that initiates tumor formation in any given dog.
Age and Breed Risk
Apudomas are predominantly reported in older dogs, with most cases occurring in animals over seven years of age. The relationship between aging and neuroendocrine tumor development likely reflects the cumulative effect of years of cellular activity on the regulatory mechanisms that normally prevent abnormal proliferation.
There is no single breed that is clearly and consistently over-represented across all types of apudoma in dogs. However, certain endocrine and neuroendocrine tumor types do show breed associations. Gastrinomas in particular have been associated with a higher frequency in some larger breeds, though the data are limited by the rarity of these tumors.
Any dog of any breed can develop an apudoma, and age remains the most consistently identified risk factor in the available clinical literature.
Tumor Development at the Cellular Level
APUD cells in the gastrointestinal tract are normally quiescent, maintaining their hormone-producing function within tight regulatory limits. Apudoma formation begins when one or more of these cells acquires mutations that disable the normal checkpoints controlling cell division.
As the mutant cell divides, it produces daughter cells that inherit the same mutations and the same tendency toward uncontrolled proliferation. Over time, a discrete mass forms. Because the daughter cells retain the functional characteristics of their APUD cell ancestors, including the ability to produce hormones and peptides, the resulting tumor is not just a structural mass but a hormonally active one.
The specific mutations involved in canine apudoma development are not fully characterised in the veterinary literature, reflecting both the rarity of the tumors and the complexity of the neuroendocrine cell population from which they arise. Environmental factors, chronic mucosal irritation, and genetic susceptibility likely all contribute in varying combinations to the overall risk in any individual dog.
Diagnosing Intestinal Apudomas in Dogs
Apudoma diagnosis is one of the more challenging tasks in veterinary gastroenterology, for several reasons. The tumors are rare, so they may not be the first differential considered. They can be small and difficult to visualise, even with imaging. And their hormonal effects may cause secondary conditions, such as ulceration, that are treated as primary diagnoses before the underlying tumor is identified.
A key clinical clue is the pattern of symptoms not responding as expected to standard management. A dog treated appropriately for gastric ulceration whose ulcers keep recurring or fail to heal should be investigated for a gastrin-secreting apudoma. A dog with chronic diarrhoea and weight loss that does not respond to standard inflammatory bowel disease management should be considered for neuroendocrine tumor investigation.
Imaging Techniques
Abdominal ultrasound is the primary first-line imaging tool for suspected intestinal apudomas. It allows evaluation of the gastrointestinal wall layers, identification of focal masses or nodules, and assessment of regional lymph nodes and other abdominal organs for metastatic disease.
Apudomas can be small and may be located in the deep layers of the intestinal wall rather than projecting into the lumen. This can make them challenging to identify on ultrasound, and a negative ultrasound result does not definitively exclude the diagnosis in a dog with a strongly suggestive clinical picture.
CT scanning provides superior sensitivity for detecting small neuroendocrine tumors and is the preferred staging modality in human medicine for this tumor type. In veterinary medicine, CT is increasingly used at referral centres for dogs where ultrasound has been inconclusive but clinical suspicion remains high, or where surgical planning requires detailed anatomical mapping.
Plain abdominal radiographs are performed as part of the routine workup and may show signs of intestinal obstruction, displacement of intestinal loops, or free gas in the abdomen if perforation has occurred. They do not identify apudomas directly.
Endoscopy and Biopsy
Endoscopy of the stomach and accessible portions of the intestinal tract allows direct visualisation of the mucosal surface. Severe or recurrent ulceration in the absence of common explanations, such as non-steroidal anti-inflammatory drug use, is a finding that should increase clinical suspicion for a gastrin-secreting apudoma. Surface biopsies taken during endoscopy may identify abnormal mucosal or submucosal tissue.
Tissue biopsy with histopathology is required for definitive diagnosis. Because neuroendocrine tumors have a distinctive microscopic appearance, including characteristic cell arrangements and staining patterns for neuroendocrine markers such as chromogranin A and synaptophysin, histopathological examination by a veterinary pathologist is the most reliable way to confirm the diagnosis and characterise the tumor type.
Hormone assays measuring circulating levels of specific peptides such as gastrin may provide supporting diagnostic information in dogs with suspected gastrin-secreting apudomas, though validated assays are not uniformly available in all veterinary settings.
Fine needle aspiration of identifiable masses may provide cytological information useful for initial characterisation, though histopathology remains the gold standard for definitive tumor typing in this disease.
Treatment for Apudomas in Dogs
Treatment decisions for apudomas depend on the tumor type, its location and size, the degree of hormonal disruption it is causing, and the extent of spread at the time of diagnosis.
Surgical Treatment
Surgical excision is the primary and most effective treatment when the apudoma is localised and technically accessible.
For intestinal apudomas, surgery involves resection of the affected bowel segment along with the tumor and reconstruction of gut continuity. For gastric apudomas, the approach depends on the location and size of the mass within the stomach wall.
The goals of surgery are to remove the primary hormone-secreting mass, thereby eliminating or significantly reducing the hormonal drive behind the secondary complications such as ulceration, to obtain definitive tissue for histopathological diagnosis, and to assess the extent of intra-abdominal disease directly.
Because apudomas may be small and occasionally multifocal, thorough intraoperative exploration of the entire abdominal cavity, including the intestinal tract, mesentery, liver, and regional lymph nodes, is an important part of the surgical procedure.
Complete surgical excision, when achievable, offers the best available long-term outcome. In dogs with confirmed metastatic disease, debulking surgery may still improve hormonal control and quality of life even when a cure is not the realistic goal.
Chemotherapy and Supportive Therapy
For dogs with confirmed malignant apudomas and metastatic disease, systemic cancer therapy may be considered as part of the broader management plan.
Chemotherapy protocols for canine gastrointestinal neuroendocrine tumors are not as well standardised as for more common canine cancers, reflecting the rarity of the disease. Agents used in other neuroendocrine tumor settings in veterinary medicine include doxorubicin-based combinations, and consultation with a veterinary oncologist is important for dogs where systemic treatment is being considered.
Targeted therapies, including somatostatin analogues, which are used in human neuroendocrine tumor management to suppress hormone secretion, have been explored in some veterinary cases and may have a role in controlling hormonal symptoms even when complete tumor removal is not possible. The availability and clinical evidence for these agents in veterinary patients continues to develop.
Supportive Management
Supportive management addresses the secondary consequences of apudoma, particularly those arising from abnormal hormone secretion.
For dogs with gastrin-secreting apudomas causing excessive acid production, proton pump inhibitors such as omeprazole are used to suppress stomach acid and allow ulcers to heal. These medications must often be maintained long-term in dogs where the underlying tumor cannot be fully removed, as ulcers will recur if acid suppression is discontinued without addressing the hormonal driver.
Dietary management, including highly digestible, low-acid-producing diets, can support gastrointestinal healing. Pain management, nutritional support for malnourished dogs, and fluid therapy for dehydration are all components of appropriate supportive care.
Dogs with apudomas that are causing significant nutritional compromise before or after surgery may benefit from appetite stimulants, nutritional supplementation, or in severe cases, assisted feeding during the stabilisation period.
Related Products
Prognosis for Dogs with Apudomas
The prognosis for dogs with intestinal apudomas varies considerably and is shaped by multiple factors, including tumor type, extent of spread, completeness of surgical resection, and the dog’s overall health at the time of diagnosis.
For dogs with localised apudomas that are completely surgically excised, the prognosis can be relatively favourable. Removal of the hormone-secreting mass eliminates the primary driver of the secondary complications, and many dogs experience significant improvement in digestive symptoms and quality of life following successful surgery.
For dogs with malignant apudomas and confirmed metastatic spread, the prognosis is more guarded. The goal of treatment shifts from cure to meaningful extension of comfortable life, with hormonal control and symptom management as the primary objectives.
The rarity of apudomas means that large-scale outcome data is limited in veterinary medicine, and individual prognosis should be discussed with a veterinary oncologist and gastroenterologist who can integrate the specific findings of each case.
Early diagnosis, before the tumor has caused extensive secondary damage from hormonal disruption, remains the factor most likely to improve the clinical trajectory regardless of tumor type.
Monitoring Digestive Health in Dogs
Persistent digestive symptoms that do not respond to standard management are not symptoms to keep treating without a diagnosis.
Any dog experiencing recurrent vomiting, chronic diarrhoea, unexplained weight loss, or repeated gastric ulceration over a period of several weeks deserves a thorough gastrointestinal workup, including abdominal imaging. The threshold for investigation should be lower in dogs over seven years of age given the increased risk of neoplastic conditions in this age group.
Between veterinary visits, track your dog’s symptoms accurately. Note the frequency, timing, and character of vomiting or diarrhoea. Document any episodes of apparent abdominal pain. Monitor body weight regularly and note any changes. This information is directly useful to the veterinary team and helps identify patterns that may not be apparent from a single examination.
For any dog with unexplained digestive symptoms, prompt evaluation is always preferable to prolonged empirical management without diagnosis.
For context on other conditions that can affect digestion and general health in dogs, VOSD’s articles on urinary problems in dogs and foreign objects stuck in the throat in dogs are part of VOSD’s broad clinical resource library for informed dog owners. And for a reminder of what is possible when a dog in desperate need receives proper care and attention, the story of the VOSD rescue of 23 starving dogs in Bengaluru is a powerful example of what early intervention and committed care can achieve.
Can Intestinal Apudomas Be Prevented?
No. There is no known way to prevent apudomas from developing in dogs.
Because the tumor arises from spontaneous abnormal proliferation of neuroendocrine cells in the gastrointestinal tract, and because the specific genetic and environmental factors that trigger this in any given dog are not clearly established, prevention through dietary modification, supplementation, or lifestyle change is not supported by current evidence.
What is within reach is earlier detection, and for a condition where secondary damage from hormonal disruption accumulates over time, earlier detection genuinely improves the clinical picture in meaningful ways.
The dog whose apudoma is found before it has caused extensive ulceration, significant nutritional depletion, or widespread metastasis has more options and a better starting point than the dog whose diagnosis is delayed.
That is the most powerful tool available. Not prevention. But attention, action, and a veterinary team willing to look further when the obvious answers are not holding up.
